NASDAQ:IRWD - Ironwood Pharmaceuticals, Inc.
$11.24
 $0.11
+0.99%
4:00PM EDT
2019-04-18
Ironwood Pharmaceuticals, Inc. is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases. It operates in human therapeutics business segment. Its product, linaclotide, is available to adult men and women suffering from IBS C or CIC in the United States under the trademarked name LINZESS, and is available to adult men and women suffering from IBS C in certain European countries under the trademarked name CONSTELLA. It is also advancing IW-3718, a gastric retentive formulation of a bile acid sequestrant with the potential to provide symptomatic relief in patients with uncontrolled GERD. Its vascular/fibrotic programs include IW-1973 and IW-1701, which targets soluble guanylate cyclase (sGC). Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  IRWD     avg for
industry  
  avg for
sector  
42 stocks weight:  3. 45   203. 85   241. 91  
42 stocks rank:  3. 21 K 1. 44 K 1. 05 K
# analyst opinions:  11. 00   14. 51   13. 97  
mean recommendation:  2. 60   2. 09   2. 01  

quick ratio:  2. 13   5. 27   1. 81  
current ratio:  2. 23   5. 62   2. 25  

target price low:  12. 00   84. 80   115. 21  
target price avg:  15. 82   111. 51   137. 51  
target price high:  19. 00   135. 81   157. 84  
1-yr high:  17. 65   114. 23   138. 78  
last close:  11. 24   87. 66   116. 69  
50-day avg:  11. 70   95. 54   123. 44  
200-day avg:  12. 75   94. 25   121. 11  
1-yr low:  7. 80   72. 78   98. 34  
volume:  717. 31 K 4. 11 M 8. 07 M
50-day avg volume:  1. 59 M 2. 76 M 5. 02 M
200-day avg volume:  1. 47 M 2. 92 M 4. 59 M

1-day return:  0. 99 % -0. 41 % 0. 07 %
this week return:  -2. 09 % -5. 74 % -4. 11 %
12-wk return:  4. 44 % 1. 61 % -0. 05 %
52-wk return:  -24. 02 % 3. 12 % 8. 78 %

enterprise value (EV):  1. 98 B 48. 94 B 114. 64 B
market cap:  1. 75 B 43. 07 B 104. 73 B
EBITDA:  -88. 04 M 4. 45 B 8. 01 B
enterprise multiple (EV/EBITDA):  -22. 48   4. 22   12. 73  
enterprise/revenue (EV/R):  5. 71   63. 17   12. 84  
total revenue:  346. 64 M 10. 62 B 38. 47 B
total debt:  413. 92 M 12. 24 B 16. 73 B
net income (common):  -282. 37 M 2. 20 B 4. 20 B

shares outstanding:  155. 63 M 571. 70 M 1. 24 B
shares:  150. 85 M 571. 81 M 1. 23 B
shares short:  14. 24 M 10. 17 M 13. 00 M
shares short prior month:  14. 52 M 9. 54 M 17. 33 M
short ratio:  10. 79   5. 41   3. 28  
short % of float:  17. 50 % 5. 45 % 2. 38 %
total cash/share:  1. 12   11. 14   9. 33  
total cash:  173. 17 M 6. 71 B 7. 15 B
free cash flow:  -30. 49 M 3. 58 B 2. 96 B
operating cash flow:  -70. 88 M 4. 15 B 4. 30 B

book value:  -1. 27   12. 78   26. 92  
price/book:  -8. 84   3. 06   -1. 74  
operating margins:  -29. 50 % -725. 35 % -89. 04 %
EBITDA margins:  -25. 40 % 10. 94 % 22. 51 %
profit margins:  -81. 46 % 7. 81 % 10. 57 %
gross margins:  42. 45 % 37. 08 % 55. 70 %

1-yr max volatility:  -18. 09 % --- ---
1-yr mean volatility:  -0. 04 % 0. 03 % 0. 04 %

1-yr EPS:  -1. 85   2. 40   4. 10  
forward EPS:  0. 45   3. 97   7. 13  
P/E:  -6. 08   13. 63   22. 72  
forward P/E:  24. 98   -15. 95   13. 99  
PE/G:  -0. 16   -1. 65   -1. 32  
growth:  38. 70 % 127. 12 % 29. 61 %
earnings high:  -0. 09   1. 00   1. 66  
earnings avg:  -0. 18   0. 77   1. 53  
earnings low:  -0. 24   0. 50   1. 39  
revenue high:  93. 10 M 2. 68 B 10. 78 B
revenue avg:  80. 85 M 2. 59 B 10. 57 B
revenue low:  72. 60 M 2. 49 B 10. 36 B
return on assets:  -13. 63 % -2. 75 % 4. 55 %
revenue growth:  38. 70 % 92. 86 % 18. 96 %
revenue/share:  2. 27   13. 29   55. 46  

beta (1yr vs S&P500):  1. 40   1. 25   0. 93  
sharpe (1yr):  -0. 21   0. 37   0. 70  

held % insiders:  2. 60 % 6. 39 % 3. 38 %
held % institutions:  100. 33 % 78. 14 % 68. 52 %

Research more with google or yahoo!
the data below are updated and published after 9pm EDT each trading day

2019-04-21 : IRWD
.    + 1.503 =         1.503 :: INITIAL WEIGHT
.   + 43.298 =        44.801 :: inverse volume-to-price addition
.   + 40.847 =        85.647 :: spline projection addition
.    x 2.824 =       241.897 :: 13 weeks' performance factor
.    x 0.854 =        206.59 :: one-year gains+dividend factor
.    x 1.431 =       295.718 :: industry recommendation factor
.    x 1.131 =       334.406 :: symbol recommendation factor
.     x 1.09 =       364.625 :: EV/R factor
.    x 0.999 =       364.128 :: return on assets factor
.    x 2.403 =       874.826 :: revenue growth factor
.    x 2.396 =      2096.364 :: current ratio factor
.    x 1.374 =      2880.574 :: quick ratio factor
.    x 1.045 =      3011.101 :: short ratio factor
.    x 1.912 =      5756.126 :: price-to-book factor
.    x 2.066 =     11889.764 :: P/E weight
.    x 1.589 =     18888.712 :: PE/G factor
.    x 1.494 =     28226.809 :: beta factor
.     x 0.21 =      5931.194 :: sharpe factor
.     x 1.26 =       7474.26 :: target low factor
.    x 1.213 =      9064.624 :: target mean factor
.    x 1.083 =      9817.802 :: target high factor
.     x 1.31 =      12860.22 :: industry 2-weeks return factor
.    x 0.952 =     12245.512 :: "drift" penalty 1 days ago
.    x 0.983 =     12034.386 :: overall "drift" factor
.    x 0.999 =      12025.28 :: largest single-day jump factor
.    x 0.168 =      2024.458 :: low price factor
.      x 1.0 =      2024.129 :: factor hist industry gain for week 16
.   cubeRoot =         12.65 :: reduced to standardize
.   + 11.354 =        24.003 :: upcoming earnings report
.   - 20.555 =         3.449 :: add/subtract for performance
.                      3.449 :: FINAL WEIGHT for NASDAQ:IRWD


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org